Lucinda J. Billingham

University of Birmingham - Cancer Research UK Clinical Trials Unit

SCHOLARLY PAPERS

2

DOWNLOADS

133

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

Immunogenicity of SARSCoV2 Third Dose Vaccine Strategies in Immunocompromised Patients with Suboptimal Immunity Following Two Doses (OCTAVE-DUO): An Open-Label, Multi-Centre, Randomised, Controlled Phase III Trial

Number of pages: 50 Posted: 10 Nov 2023
University of Glasgow, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London, University of Glasgow, University of Sheffield - Department of Infection, Immunity & Cardiovascular Disease, Sheffield Teaching Hospitals NHS Foundation Trust, Southampton University, University of Birmingham, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Birmingham - Institute of Cancer and Genomic Sciences, University of Oxford - Wellcome Trust Centre for Human Genetics, The Francis Crick Institute, Francis Crick Institute - Cell Biology of Infection Laboratory, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Birmingham - Institute of Immunology and Immunotherapy, University of Birmingham, University of Oxford - Nuffield Department of Medicine, University of Oxford, Mahidol University - Mahidol-Oxford Tropical Medicine Research Unit, University of Leeds, Guy's Hospital - British Society of Blood and Marrow Transplantation and Cellular Therapy, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Birmingham - Cancer Research UK Clinical Trials Unit, University of Birmingham, University of Saint Etienne - Centre Hospitalier Universitaire de Saint-Étienne, University of Oxford, University College London - Research Department of Hematology, University of Leicester - Leicester General Hospital, University of London - Institute of Infection and Immunity, Royal Free Hospital, University of Southampton - University Hospital Southampton NHS Foundation Trust, University of Glasgow - College of Medical, Veterinary & Life Sciences, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Peter Medawar Building for Pathogen Research, Imperial College London - Imperial College Healthcare NHS Trust, University of Oxford - Nuffield Department of Medicine, University of Southampton - University Hospital Southampton NHS Foundation Trust, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Glasgow - College of Medical, Veterinary & Life Sciences, Imperial College London, Imperial College London, University of Birmingham, University of Glasgow and University of Birmingham - NIHR Birmingham Biomedical Research Centre and Institute of Cancer and Genomic Sciences
Downloads 114 (498,310)

Abstract:

Loading...

COVID-19, Immunology, Clinical trial, Vaccine

2.

Olaparib as Maintenance Treatment in Patients with Chemosensitive Small Cell Lung Cancer (STOMP): A Randomised, Double-Blind, Placebo-Controlled Phase II Trial

Number of pages: 18 Posted: 17 Mar 2022
University of Sheffield, affiliation not provided to SSRN, University of Sheffield, University of Glasgow - Beatson West of Scotland Cancer Centre, University Hospitals of Leicester NHS Trust, affiliation not provided to SSRN, Maidstone and Tunbridge Wells NHS Trust, NHS Foundation Trust - Royal Marsden Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN and University of Birmingham - Cancer Research UK Clinical Trials Unit
Downloads 19 (1,081,766)
Citation 1

Abstract:

Loading...

small cell lung cancer, maintenance treatment, olaparib, clinical trial